相关临床试验
210
41 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1905
进行中（未招募）
23
10.9%
已完成
99
47.1%
尚未招募
18
8.6%
招募中
41
19.5%
Unknown
29
13.8%
暂无批准数据
- Singapore launched a $350 million healthy longevity grand challenge in May 2026 under its RIE2030 framework to extend healthspan and shorten years lived in poor health. - The initiative aims to validate biological age clocks and biomarkers for Asian populations, enabling primary care doctors to detect cognitive and physical decline before symptoms appear. - Alexandra Hospital's year-long programme demonstrated measurable improvements in biomarkers, fitness, and biological age through personalised lifestyle interventions rather than high-tech quick fixes. - Researchers are testing precision geromedicine interventions, including low-dose rapamycin and multivitamins, while embedding lifestyle medicine into the medical curriculum to democratise longevity care.
- A longitudinal study of 502 children from the GUSTO birth cohort found that higher screen viewing at age 1 showed the strongest association with poorer later academic performance and weaker working memory. - Screen exposure at ages 2 and 3 showed no significant links, but associations re-emerged at age 6, coinciding with the transition into formal schooling. - Researchers suggest infancy and the start of formal education may be sensitive periods when screen habits carry longer-term implications for learning and memory. - The authors emphasize that "less is better" for screen exposure and call for future research on content quality, device type, and parental co-viewing.
- Dr. Andrea Maier opened a new clinical trial center at the National University of Singapore in 2025, enabling multiple long-term trials of supplements, exercise, and lifestyle interventions for health span. - Her trials enroll people whose biological age exceeds their chronological age, increasing the likelihood of detecting meaningful effects from targeted interventions. - The PROMETHEUS trial's 8-week pilot protocol produced "promising results" on markers of muscle, cognitive, and immune function in 20 participants. - Maier advocates for individualized, precision-medicine plans, arguing that aging is too heterogeneous for one-size-fits-all interventions.
- L'Oréal Groupe and the NUS Academy for Healthy Longevity at NUS Medicine have announced a multi-year strategic research partnership and a new joint laboratory focused on healthy longevity science. - The laboratory integrates L'Oréal's advanced skin, scalp and hair evaluation capabilities into the Healthy Longevity Clinical Trial Centre's comprehensive longevity assessment workflow. - Co-locating skin characterisation with cardiovascular, metabolic, cognitive and musculoskeletal measures enables researchers to directly correlate skin data with systemic health indicators within the same individuals. - L'Oréal invests €1.3 billion annually in research and innovation, supported by 4,000 scientists across 22 research centres worldwide.
- NUS researchers developed y-iLight, a red-light-responsive protein that controls gene expression in yeast without requiring additional chemical cofactors. - The team overcame cross-sensitivity to blue light by engineering protein modules that suppress unwanted activation, enabling reliable multiplexed control. - Combining red and blue light systems allowed sequential control of compound production and cell separation, demonstrated with the antioxidant luteolin. - Findings published in Nature Communications pave the way for more predictable, programmable, and environmentally friendly biomanufacturing processes.
- The Molecular Imaging World Summit 2026 in Copenhagen highlighted long axial field-of-view (LAFOV) PET/CT scanners as transformative for whole-body perfusion imaging and systemic disease evaluation across cancer, cardiovascular, and neurodegenerative conditions. - ImmunoPET with LAFOV scanners unlocks unprecedented opportunities for personalized cancer therapies by targeting both tumor antigens and immune cells, according to Dr. Erik Aarntzen of University Medical Center Groningen. - PET/MRI is emerging as the platform of choice for neuromolecular imaging, enabling simultaneous acquisition of molecular and multiparametric structural data with significantly reduced radiation exposure. - Global access to theranostics is expanding through innovative financing models, strategic partnerships, and flexible delivery pathways, with programs demonstrating success in both industrialized and resource-limited settings.
- A landmark study published in the New England Journal of Medicine reports that 9 of 11 pediatric patients with T-cell acute lymphoblastic leukemia achieved remission following treatment with BE-CAR7, a base-edited CAR T-cell therapy. - Base editing, which changes a single DNA letter with greater precision than CRISPR, was used to engineer donor T-cells capable of hunting down and eliminating malignant T-cells without damaging both DNA strands. - Seven patients remained disease-free between three months and three years after treatment, with the first recipient, 13-year-old Alyssa Tapley, now cancer-free four years post-treatment. - The breakthrough highlights base editing's therapeutic potential while intensifying global debate over the ethical boundaries of gene-editing technologies, including heritable genome modification.
- Researchers at the National University of Singapore developed LEAF, a nanosized thylakoid system extracted from spinach that produces NADPH when exposed to ambient light. - In a mouse model of dry eye disease, twice-daily LEAF drops doubled NADPH levels, reversed corneal damage, and outperformed an approved therapeutic drug. - LEAF reduced reactive oxygen species within 30 minutes of light exposure and boosted NADPH roughly 20-fold in tears from dry eye patients. - The plant-derived nanoparticles showed no immune rejection, remained stable for two weeks at room temperature, and require no external device or power source.
- Scientists broadly agree that biological age is a valid concept distinct from chronological age, measurable through various molecular clocks that track processes like DNA methylation and chronic inflammation. - Epidemiological studies show that accelerated biological aging, as measured by clocks such as GrimAge and iAge, can predict higher risks of cognitive decline, heart disease, and frailty. - Experts warn that consumer-available tests capture only individual facets of aging and are open to misinterpretation, with single age estimates providing limited clinical value without functional health metrics. - Researchers advocate for better consumer education, healthcare professional guidance, or certification systems to ensure biological aging clocks fulfill their potential role in preventative medicine.
- A*STAR and NUS have launched a joint synthetic biology lab called PRIME to transform research breakthroughs into commercially viable products using bioengineered yeast and fungi as "cell factories." - The global synthetic biology market is projected to grow to over US$60 billion by 2030, with the broader bioeconomy expected to contribute up to US$4 trillion annually within the next decade. - Led by synthetic biology pioneer Professor Jay Keasling, the lab will leverage AI-guided enzyme engineering and scalable microbial platforms to produce complex molecules previously too costly to manufacture. - The lab will also serve as a training ground for future scientists through joint supervision, internships, and fellowships in synthetic biology, metabolic engineering, and industrial biomanufacturing.
